Broader aspirin professional labeling indications urged by joint advisory committee.

ASPIRIN PROFESSIONAL LABELING INCLUSION OF STABLE ANGINA PECTORIS was one of several recommendations made by FDA's Nonprescription Drugs and Cardiovascular & Renal Drugs Advisory Committees at a joint meeting Jan. 23 in Gaithersburg, Md. The joint advisory committee also voted to recommend that professional labeling for aspirin include an indication for prevention of recurrent vascular events including myocardial infarction (MI) and stroke and use in people who have had revascularization for symptomatic coronary disease.